Shionogi Inc.
12
2
3
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
17%
2 trials in Phase 3/4
33%
3 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID
Role: collaborator
Pharmacokinetic Analysis of Cefiderocol in Patients With Acute Burn Injuries
Role: collaborator
P1, DDI & MAD PK and Safety Study of Xeruborbactam Oral Prodrug in Combo With Ceftibuten in Healthy Participants
Role: collaborator
A DDI Study to Investigate PK and Safety of Cefiderocol in Combination With Xeruborbactam in Healthy Adult Participants
Role: collaborator
A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment
Role: collaborator
Mass Balance Study of [14C]Xeruborbactam (QPX7728) in Healthy Adult Male Participants
Role: collaborator
PK & Safety Study of Xeruborbactam Oral Prodrug Combined With Ceftibuten in Participants With Renal Impairment
Role: collaborator
Cefiderocol Plasma Concentrations in Patients Receiving Renal Replacement Therapy
Role: collaborator
Cefiderocol PK in Patients on ECMO
Role: collaborator
Cefiderocol Pharmacokinetics in Adult Patients With Cystic Fibrosis
Role: collaborator
Use of Fenofibrate for Primary Biliary Cirrhosis
Role: collaborator
Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation
Role: collaborator
All 12 trials loaded